NASDAQ:AVCO Avalon GloboCare (AVCO) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free AVCO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.38▼$0.7052-Week Range N/AVolume441,100 shsAverage Volume142,644 shsMarket Capitalization$52.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Avalon GloboCare alerts: Email Address Ad Huge AlertsTrending Stocks Sent To You In Real Time Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next Alert About Avalon GloboCare Stock (NASDAQ:AVCO)Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.Read More Ad DTImy top trade on these 9 tickersThis indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.Click Here for this Powerful Workshop AVCO Stock News HeadlinesSeptember 13, 2023 | markets.businessinsider.comAvalon’s Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter DeviceSeptember 5, 2023 | markets.businessinsider.comAvalon GloboCare Announces Notice of Publication for Key U.S. Patent Filed Jointly with the Massachusetts Institute of Technology (MIT)March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.August 30, 2023 | finance.yahoo.comAvalon’s Laboratory Services MSO Launches Innovative Laboratory Test for TuberculosisJuly 24, 2023 | finance.yahoo.comAvalon’s Laboratory Services MSO Acquires Texas Lab with Significant Potential GrowthApril 22, 2023 | investing.comAvalon Globocare Corp (ALBT)March 3, 2023 | finance.yahoo.comAvalon GloboCare to Participate in the 35th Annual Roth ConferenceMarch 1, 2023 | detroitnews.comAvalon reopens in Midtown on Canfield Wednesday with 25 cent cookiesMarch 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionNovember 9, 2022 | finance.yahoo.comAvalon GloboCare Announces NASDAQ Ticker Symbol Change from “AVCO” to “ALBT”November 8, 2022 | proactiveinvestors.comAvalon Globocare enters 'transformative' deal to acquire majority stake in Laboratory Services MSONovember 8, 2022 | proactiveinvestors.comBiotech junior climbs on acquisition deal: Proactive’s daily small cap moversNovember 8, 2022 | seekingalpha.comAvalon GloboCare to acquire a 60% interest in Laboratory Services MSO, LLCNovember 8, 2022 | proactiveinvestors.comAvalon GloboCare to acquire majority interest in Laboratory Services MSO in 'transformative' deal worth $31MNovember 8, 2022 | finance.yahoo.comEXCLUSIVE: Avalon GloboCare Acquires Majority Stake In Premier Reference LaboratoryNovember 8, 2022 | finance.yahoo.comAvalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 MillionNovember 8, 2022 | finance.yahoo.comInvestors in Avalon GloboCare (NASDAQ:AVCO) from five years ago are still down 72%, even after 32% gain this past weekOctober 19, 2022 | finance.yahoo.comAvalon Globocare to Present at the LD Micro Main Event XV on October 26thSeptember 29, 2022 | proactiveinvestors.comAvalon GloboCare gets notice of allowance from US patent office for QTY fusion platformSeptember 29, 2022 | finance.yahoo.comAvalon GloboCare Receives Allowance for Joint U.S. PatentSeptember 16, 2022 | seekingalpha.comAVCO Avalon GloboCare Corp.September 10, 2022 | uk.finance.yahoo.comAvalon GloboCare Corp. (AVCO)September 9, 2022 | nasdaq.comInvestors in Avalon GloboCare (NASDAQ:AVCO) have unfortunately lost 82% over the last five yearsAugust 8, 2022 | proactiveinvestors.comAvalon GloboCare says its co-developed QTY code protein code technology featured in Chemical ReviewsAugust 8, 2022 | finance.yahoo.comAvalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical SocietyJune 30, 2022 | ca.proactiveinvestors.comAvalon GloboCare reveals new study using AI-powered protein design technology targeting glucose transporter against cancerJune 30, 2022 | finance.yahoo.comAvalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against CancerSee More Headlines Receive AVCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalon GloboCare and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2018Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Management consulting services Sub-IndustryN/A Current SymbolNASDAQ:AVCO CUSIPN/A CIK1630212 Webwww.avalon-globocare.com Phone(732) 780-4400Fax732-780-5600Employees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,090,000.00 Net Margins-599.86% Pretax Margin-599.79% Return on Equity-444.65% Return on Assets-70.05% Debt Debt-to-Equity Ratio14.00 Current Ratio0.23 Quick Ratio0.23 Sales & Book Value Annual Sales$1.39 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / BookN/AMiscellaneous Outstanding Shares99,215,000Free Float28,872,000Market Cap$52.18 million OptionableNot Optionable Beta0.81 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. David K. Jin M.D. (Age 54)Ph.D., CEO, Pres & Director Comp: $360kMs. Luisa Ingargiola (Age 55)Chief Financial Officer Comp: $350kMs. Meng Li (Age 44)COO, Sec. & Director Comp: $340kKey CompetitorsAeries TechnologyNASDAQ:AERTRyvylNASDAQ:RVYLATIFNASDAQ:ATIFInformation Services GroupNASDAQ:IIIreAlpha TechNASDAQ:AIREView All Competitors AVCO Stock Analysis - Frequently Asked Questions How were Avalon GloboCare's earnings last quarter? Avalon GloboCare Corp. (NASDAQ:AVCO) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.03) EPS for the quarter. The company had revenue of $0.41 million for the quarter. Avalon GloboCare had a negative trailing twelve-month return on equity of 444.65% and a negative net margin of 599.86%. What other stocks do shareholders of Avalon GloboCare own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avalon GloboCare investors own include Amarin (AMRN), Axsome Therapeutics (AXSM), Clovis Oncology (CLVS), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV), Exxon Mobil (XOM), Intercept Pharmaceuticals (ICPT), Occidental Petroleum (OXY), REGENXBIO (RGNX) and Adamis Pharmaceuticals (ADMP). This page (NASDAQ:AVCO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.